UCB SA - BNP Paribas Fortis

More documents

Recommendations

Info

A11250830/2.25/23 Oct 2009 6 TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................................. 6 PART I: SUMMARY........................................................................................................................................ 7 PART II: RISK FACTORS............................................................................................................................ 14 PART III: DOCUMENTS INCORPORATED BY REFERENCE ............................................................ 31 PART IV: TERMS AND CONDITIONS OF THE BONDS........................................................................ 34 PART V: CLEARING .................................................................................................................................... 48 PART VI: DESCRIPTION OF ISSUER ...................................................................................................... 49 PART VII: MANAGEMENT AND CORPORATE GOVERNANCE ....................................................... 92 PART VIII. PRINCIPAL SHAREHOLDERS .......................................................................................... 105 PART IX: RELATED PARTY TRANSACTIONS .................................................................................... 107 PART X: ASSOCIATED COMPANIES AND SHAREHOLDINGS........................................................ 108 PART XI: DESCRIPTION OF THE SHARES AND ARTICLES OF ASSOCIATION.........................117 PART XII: USE OF PROCEEDS ............................................................................................................... 124 PART XIII: TAXATION.............................................................................................................................. 125 PART XIV: SUBSCRIPTION AND SALE................................................................................................. 131 PART XV: GENERAL INFORMATION ................................................................................................... 137 Page
A11250830/2.25/23 Oct 2009 7 PART I: SUMMARY This summary must be read as an introduction to the listing and offering prospectus dated 23 October 2009 (the “Prospectus”) and any decision to invest in the 5.75 per cent. fixed rate bonds due 27 November 2014 (the “Bonds”) should be based on a consideration of this Prospectus as a whole, including the documents incorporated by reference. Following the implementation of the relevant provisions of the Prospectus Directive in each Member State of the European Economic Area (an “EEA State”), no civil liability will attach to the Responsible Persons (as defined on p. 3 of the Prospectus) in any such Member State solely on the basis of this summary, including any translation thereof, unless it is misleading, inaccurate or inconsistent when read together with the other parts of this Prospectus. Full version of this Prospectus is available on the website of the Issuer (www.ucb.com) and the website of the Luxembourg Stock Exchange (www.bourse.lu). Where a claim relating to the information contained in this Prospectus is brought before a court in an EEA State, the plaintiff may, under the national legislation of the EEA State where the claim is brought, be required to bear the costs of translating the Prospectus before the legal proceedings are initiated. Terms defined in "Terms and Conditions of the Bonds" below shall have the same meaning where used in this Summary. 1. BUSINESS DESCRIPTION OF THE ISSUER UCB S.A. is a Belgian corporation (“naamloze vennootschap”/“société anonyme”) having its registered office at 60 Allée de la Recherche, 1070 Brussels, Belgium and registered with the register of legal persons (“rechtspersonenregister”/“registre des personnes morales”) under enterprise number (“ondernemingsnummer”/“numéro d’entreprise”) VAT-BE 0403.053.608 RLP Brussels. UCB S.A. was incorporated on 26 May 1925. UCB’s Ordinary Shares have been listed on the Belgian Stock Exchange (now Euronext Brussels) since incorporation. The UCB Group is a global biopharmaceutical company, headquartered in Brussels. The UCB Group develops and markets human pharmaceutical products for the treatment of severe central nervous system (CNS) and immunology disorders. The strategy of the UCB Group is driven by its ambition to form a leading global next generation biopharmaceutical company focused on the treatment of severe diseases. The UCB Group differentiates itself by focusing on a patient-driven approach to developing treatments for a range of severe CNS and immunology disorders. The key marketed products of the UCB Group are Vimpat®, Neupro® and Keppra® (including Keppra®XR) for CNS diseases. For immunology, the key marketed product is Cimzia®. Other significant marketed products include Zyrtec®, Xyzal®, Tussionex®, venlafaxine, Nootropil®, Innovair® and MetadateCD. The currently marketed products of the UCB Group are supplemented by a research and development pipeline focusing on the following CNS diseases: epilepsy, diabetic neuropathic pain, restless legs syndrome and Parkinson’s disease. Research and development is also carried out in the following immunology disorders: Crohn’s disease, rheumatoid arthritis, systemic lupus erythematosus, bone loss disorders and other autoimmune diseases. Through its partnership with Pfizer, UCB also participates in the over-active bladder disease area. The UCB Group believes that the concentration of its research and development efforts on a limited range of severe diseases increases the likelihood of significant, high- A4 - 5.1
Page 1 and 2: A11250830/2.25/23 Oct 2009 UCB SA (
Page 3 and 4: A11250830/2.25/23 Oct 2009 3 RESPON
Page 5: A11250830/2.25/23 Oct 2009 5 WARNIN
Page 9 and 10: Specified Denomination per Bond Min
Page 11 and 12: Trading on the regulated market of
Page 13 and 14: - Reliance on the procedures of the
Page 15 and 16: and federal governmental entities,
Page 17 and 18: If any of the UCB Group’s major p
Page 19 and 20: The UCB Group relies upon third-par
Page 21 and 22: other U.S. federal and state govern
Page 23 and 24: either to remediate certain sites o
Page 25 and 26: (iii) have sufficient financial res
Page 27 and 28: (i) EU Savings Directive Under the
Page 29 and 30: (o) The Domiciliary Agent is not re
Page 31 and 32: PART III: DOCUMENTS INCORPORATED BY
Page 33 and 34: • Press release of 26 June 2009:
Page 35 and 36: The Bonds constitute direct, uncond
Page 37 and 38: “Interest Payment Date” has the
Page 39 and 40: When interest is required to be cal
Page 41 and 42: "Calculation Agent" means Fortis Ba
Page 43 and 44: The Issuer reserves the right under
Page 45 and 46: any step is taken to enforce it (in
Page 47 and 48: 12 Notices Notices to the Bondholde
Page 49 and 50: 1. SUMMARY PART VI: DESCRIPTION OF
Page 51 and 52: Marketing & selling expenses Resear
Page 53 and 54: In 2008, the Issuer announced sever
Page 55 and 56: Issuer is developing from its stron
Page 57 and 58:
Parkinson’s disease. Following a
Page 59 and 60:
Keppra® is one of the core product
Page 61 and 62:
that remission is possible with no
Page 63 and 64:
(d) Manufacturing and supply of raw
Page 65 and 66:
NET SALES FOR MAIN PRODUCTS BY REGI
Page 67 and 68:
(a) a strategic focus on severe CNS
Page 69 and 70:
ongoing and results are expected du
Page 71 and 72:
Cimzia® (certolizumab pegol) Cimzi
Page 73 and 74:
• Pfizer Inc.: The UCB Group is p
Page 75 and 76:
esearch, regulatory, manufacturing,
Page 77 and 78:
Neupro® (rotigotine; patch) Februa
Page 79 and 80:
Before a drug can qualify for marke
Page 81 and 82:
control mechanisms operate differen
Page 83 and 84:
year term following a specific regu
Page 85 and 86:
pain; which expires with the last t
Page 87 and 88:
Group. The UCB Group treats any cla
Page 89 and 90:
(g) Distilbène Litigation As of th
Page 91 and 92:
(n) Competition enquiry in France T
Page 93 and 94:
3 These Directors are representativ
Page 95 and 96:
Norman J-Ornstein was appointed to
Page 97 and 98:
Mark McDade joined the Issuer as ex
Page 99 and 100:
esults or information which is liab
Page 101 and 102:
Peter Fellner......................
Page 103 and 104:
• the closing price of the Ordina
Page 105 and 106:
A11250830/2.25/23 Oct 2009 105 PART
Page 107 and 108:
A11250830/2.25/23 Oct 2009 107 PART
Page 109 and 110:
Company name Registered office Cist
Page 111 and 112:
Company name Registered office Schw
Page 113 and 114:
Company name Registered office UCB
Page 115 and 116:
Company name Registered office UCB
Page 117 and 118:
PART XI: DESCRIPTION OF THE SHARES
Page 119 and 120:
According to article 32 of the Arti
Page 121 and 122:
Under UCB’s Articles, the Issuer
Page 123 and 124:
The Board can also determine when s
Page 125 and 126:
1. BELGIAN TAXATION PART XIII: TAXA
Page 127 and 128:
(b) Belgian tax on income and capit
Page 129 and 130:
more detailed proposal for amendmen
Page 131 and 132:
PART XIV: SUBSCRIPTION AND SALE For
Page 133 and 134:
On the date that the subscriptions
Page 135 and 136:
12. DISTRIBUTION OF THE PROSPECTUS
Page 137 and 138:
PART XV: GENERAL INFORMATION 1. App
Page 139 and 140:
A11250830/2.25/23 Oct 2009 139 Subs
Page 141 and 142:
Addressee UCB SA (the « Issuer »)
show all

UCB SA - BNP Paribas Fortis

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?